


S.Korea's Y-Biologics to globalize immuno-oncology therapeutics with French partner

July 6, 2021 | News

The license agreement grants worldwide exclusive rights to French mid-pharma Pierre Fabre to develop and commercialize human antibody Ymax[®]-ABL library owned by Y-Biologics



The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax[®]-ABL library owned by Y-Biologics.

These antibodies have been functionally validated by the Pierre Fabre R&D teams for their specific properties on a pivotal immuno-oncology target acting on the tumoral microenvironment. Pierre Fabre intends to select a new therapeutic candidate in immuno-oncology for further developments.

This licensing agreement results from the strong and now proven complementarity between the two companies that have been collaborating since 2018. The final objective pursued by Y-Biologics and Pierre Fabre is to provide patients with innovative drugs to target refractory or relapsing cancer, taking advantage of the immune infiltrate to inhibit the growth of tumor cells.

This new milestone reached by the two companies reveals the effectiveness of the scientific means put in place by Y-Biologics, associated with the high expertise of Pierre Fabre in oncology.

Young Woo Park, CEO of Y-Biologics, stated: "our first license agreement with Pierre Fabre is expected to further advance the development of innovative immuno-oncology therapeutics targeting the tumor microenvironment."

"Their library has allowed us to identify a family of human antibodies against a promising target defined by our researchers at our dedicated Center of Immunology. This new exciting license agreement will allow us to further support the development of this therapy for the benefit of patients," added Nathalie Corvaia, Head of Immuno-Oncology Research, Center of Immunology Pierre Fabre (CIPF).